NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $220,000 | -15.7% | 68,710 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $261,000 | -29.5% | 68,710 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $370,000 | -60.1% | 68,710 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $928,000 | -65.4% | 68,710 | -54.0% | 0.00% | -66.7% |
| Q3 2021 | $2,685,000 | +4.7% | 149,500 | 0.0% | 0.01% | +20.0% |
| Q2 2021 | $2,565,000 | -14.2% | 149,500 | 0.0% | 0.01% | -16.7% |
| Q1 2021 | $2,990,000 | +17.6% | 149,500 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $2,542,000 | +2.5% | 149,500 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $2,480,000 | -28.4% | 149,500 | 0.0% | 0.01% | -33.3% |
| Q2 2020 | $3,462,000 | +29.7% | 149,500 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $2,669,000 | -17.3% | 149,500 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $3,227,000 | – | 149,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |